Ph.D., Principle Scientist
SEngine Precision Medicine Se
Dr. Michael Churchill has eleven years of academic research experience at MIT, University of Michigan, Harvard Stem Cell Institute, Broad Institute, and Columbia University. He received his PhD in Cell Biology from Columbia University.
Michael will be presenting on the following:
Title: Automating a High Throughput Organoid Assay for Precision Oncology with the CyBio FeliX
PARIS: A High Throughput Organoid Assay for Precision Oncology
SEngine Precision Medicine is an innovative personalized oncology company building on cutting-edge research initially carried out at the Fred Hutchinson Cancer Research Center in Seattle, WA. SEngine’s mission is to fast-track the delivery of targeted and personalized oncology treatments with PARIS®, a CLIA approved diagnostic test engineered to help oncologists match patients with the optimal drug treatment for their unique cancer type, while also advancing the discovery and development of novel drug targets. The PARIS® test identifies the best available drugs and combinations for an individual patient’s tumor by directly measuring the effect of each drug combination on the patient’s own cancer cells. Functional data is generated using short term expansion of 3D tumoroids; which in contrast to traditional cell lines, are able to represent the heterogeneity and complexity of each tumor. We are now adapting this test to guide three separate first-in-class 48-arm clinical trials for gastrointestinal cancers (pancreatic, cholangial, and colorectal). We will present how the integration of the data across many different patients and tumor types can go beyond the benefit for the single patient and provide information to accelerate approval of a candidate drug combination.
Tuesday, January 28
12:30 PM – 1:45 PM